• Disclaimer
• SiteMap
• Home

• about us
  • Corporate Profile
  • Board of Directors
• technology
  • GIPET®
  • Strategic Partnering
• portfolio
  • Product Pipeline
  • Strategic Partnering
  • Orazol™ (Breast Cancer)
  • Orazol™ (Bone Metastases)
  • Almerol™ (MER-103)
  • Acyline (MER-104)
  • MER-102
• investor relations
  • Corporate Profile
  • Share Information
  • Annual Reports /
    Financial Information
  • Financial Calendar
  • Investor Alert
  • Regulatory News
  • Corporate Governance
  • Analyst Coverage
  • Advisors and Registrars
  • Ownership Summary
  • Rule 26 Information
• media
• contact

Regulatory News

• Print page
• Email page

Appointment of Broker and ESM Adviser

Merrion Pharmaceuticals Plc (ESM: MERR), a publicly listed product development company announces that Davy has been appointed as the Company's broker and ESM Adviser with immediate effect.

Contact Information:

Merrion Pharmaceuticals Plc.
Jonathan O'Connell, Chief Financial Officer	+353 (0)1 642 3300
Davy Corporate Finance
Ivan Murphy, Director	+353 1 679 6363

 

For further information: www.merrionpharma.com

 

<< Back to Regulatory News